Organogenesis (ORGO) Stock: Buy, Sell, or Hold?
ORGO - Organogenesis Holdings Inc. Class A Common Stock
$0.99
-0.04 (-3.57%)
▼
5d:
-0.65%
30d:
-30.06%
90d:
-61.05%
WAIT
LOW Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: Nov 05, 2026
11d
Get Alerted When ORGO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: ORGO shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: ORGO shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: ORGO is currently trading at $0.99, which is considered oversold relative to its 30-day fair value range of $1.12 to $1.44. From a valuation perspective, the stock is trading at a discount (Forward PE: -3.2) compared to its historical average (18.1). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, ORGO is in a strong downtrend. Immediate support is located at $0.93, while resistance sits at $1.28. Short-term momentum is weak, with the stock down 3.6% recently.
Market Sentiment: The stock scores a mixed 50/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $2.00 (+101.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ORGO is in a strong downtrend. Immediate support is located at $0.93, while resistance sits at $1.28. Short-term momentum is weak, with the stock down 3.6% recently.
Market Sentiment: The stock scores a mixed 50/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $2.00 (+101.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.12 -
$1.44
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
79.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (50/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.6%)
- BULLISH: Trading 101.4% below Wall St target ($2.00)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Composite score 50/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.12 -
$1.44
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.93
Resistance Level
$1.28
Current Trend
Strong Downtrend
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.20
Wall Street Target
$2.00
(+101.4%)
Revenue Growth (YoY)
-56.7%
Earnings Growth (YoY)
555.2%
Profit Margin
-18.4%
PE vs Historical
-3.2 vs 18.1
CHEAP
Share & Embed Analysis
Last updated: October 23, 2026 10:56 PM ET
Data refreshes hourly during market hours. Next update: 11:56 PM
Data refreshes hourly during market hours. Next update: 11:56 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ORGO showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
29 analysts |
$207 | 56 HOLD |
|
ELAN
Elanco Animal Health |
STRONG BUY
16 analysts |
$31 | 47 HOLD |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 65 BUY |
|
ALKS
Alkermes Plc |
STRONG BUY
19 analysts |
$56 | 38 SELL |
|
AMLX
Amylyx Pharmaceuticals I… |
STRONG BUY
12 analysts |
$43 | 54 HOLD |
